Technical Analysis for RTRX - Retrophin, Inc.

Grade Last Price % Change Price Change
grade D 19.01 2.37% 0.44
RTRX closed up 2.37 percent on Friday, May 17, 2019, on 1.23 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical RTRX trend table...

Date Alert Name Type % Chg
1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Crossed Above 20 DMA Bullish 0.00%
Outside Day Range Expansion 0.00%
20 DMA Resistance Bearish 2.37%
1,2,3 Retracement Bearish Bearish Swing Setup 2.37%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 2.37%
MACD Bullish Signal Line Cross Bullish 2.37%
Slingshot Bearish Bearish Swing Setup 2.37%
Lower Bollinger Band Touch Weakness 2.37%

Older signals for RTRX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Retrophin, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orphan drugs for the treatment of rare and life-threatening diseases. The company develops treatments for Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), Duchenne Muscular Dystrophy and other catastrophic diseases. Its products include RE-021, a small molecule angiotensin receptor blocker and selective endothelin receptor antagonist for the treatment of FSGS; and RE-024, a drug that restores the disruption in the biochemical Coenzyme A pathway caused by the non-functioning PANK2 encoded enzyme. The company also develops RE-001, a recombinant fusion protein that substitutes the dystrophin that is lacking in DMD patients; and RE-003, an investigational agent for spinal muscular atrophy. The company was founded in 2011 and is based in New York, New York.
Medicine Biopharmaceutical Medical Genetics Kidney Diseases Muscular Dystrophy Spinal Muscular Atrophy Duchenne Muscular Dystrophy Genetic Genealogy Dystrophy Channelopathies
Is RTRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 33.0
52 Week Low 17.53
Average Volume 391,753
200-Day Moving Average 23.98
50-Day Moving Average 21.013
20-Day Moving Average 18.918
10-Day Moving Average 18.462
Average True Range 0.7989
ADX 35.38
+DI 14.951
-DI 24.171
Chandelier Exit (Long, 3 ATRs ) 18.9733
Chandelier Exit (Short, 3 ATRs ) 19.9267
Upper Bollinger Band 20.1606
Lower Bollinger Band 17.6754
Percent B (%b) 0.54
BandWidth 13.136695
MACD Line -0.7226
MACD Signal Line -0.826
MACD Histogram 0.1035
Fundamentals Value
Market Cap 729.7 Million
Num Shares 38.4 Million
EPS -1.84
Price-to-Earnings (P/E) Ratio -10.33
Price-to-Sales 6.36
Price-to-Book 3.08
PEG Ratio -1.05
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 20.43
Resistance 3 (R3) 20.36 19.82 20.19
Resistance 2 (R2) 19.82 19.46 19.85 20.11
Resistance 1 (R1) 19.41 19.23 19.62 19.48 20.03
Pivot Point 18.87 18.87 18.97 18.91 18.87
Support 1 (S1) 18.47 18.51 18.67 18.54 17.99
Support 2 (S2) 17.93 18.29 17.96 17.91
Support 3 (S3) 17.52 17.93 17.83
Support 4 (S4) 17.59